CNC remains a Great Buy, thanks to its promising multi-year margin recovery prospects arising from the drastically raised premiums by the mid 30%s. While the management already expects to see "some degree of membership attrition," I am of the opinion that this is an inevitable (and temporary) pain for its future margin recovery. The raised FY2025 guidance and the bottoming in its FQ3'25 HBR imply the worst may be behind us, with FY2026 likely to bring forth improved numbers.
Shares of several major health insurers surged Monday following reports President Donald Trump could be set to unveil a healthcare proposal that would extend Affordable Care Act subsidies.
Shares of Centene Corporation (NYSE: CNC) have climbed 6.2% from their November 10 low of $34.25.
| - Industry | - Sector | Sarah M. London CEO | XBER Exchange | US15135B1017 ISIN |
| US Country | 60,400 Employees | - Last Dividend | 7 Feb 2019 Last Split | 13 Dec 2001 IPO Date |
Centene Corporation stands as a prominent healthcare enterprise catering to the essential healthcare needs of under-insured and uninsured families, commercial organizations, and military families within the United States. Distinguished by its commitment to providing comprehensive health programs and services, the company navigates through the complexity of healthcare needs across diverse populations. Established in 1984 and headquartered in Saint Louis, Missouri, Centene has carved a niche for itself in the healthcare sector by offering a wide array of services across its multiple operational segments including Medicaid, Medicare, Commercial, and Other segments. The company's focus on accessibility and quality care underlines its mission to deliver healthcare solutions that foster well-being and improve health outcomes for all its members.
Centene's product and service portfolio spans across several key areas of healthcare, addressing the needs of a vast demographic through its diversified offerings: